Trending News
News
News
New Target for Fighting Picornaviruses
Study reveals the unexpected role of a bacterial clearance pathway in the picornavirus life cycle - a potential drug target for a broad range of picornaviruses.
News
Researchers Found That the Release of Histone Proteins Is Guided by Unwrapping DNA
Using X-rays to visualize DNA and fluorescence to monitor the histone proteins, Cornell researchers found that the release of histone proteins is guided by unwrapping DNA.
News
Mayo Clinic Finds Protein That Weakens Sepsis Immune Reaction
Investigators at Mayo Clinic’s campus in Florida have identified a key molecule that, in mice, helps protect the body’s central nervous system against the runaway inflammation.
News
Protein central to immune response against tuberculosis bacteria
UT Southwestern Medical Center researchers have identified a protein that is central to the immune system’s ability to recognize and destroy the bacterium responsible for the global tuberculosis epidemic.
News
Kite And Fosun Establish Joint Venture In China
Kite Pharma and Fosun Pharma announce joint venture to develop, manufacture and commercialize Kite's lead product candidate, axicabtagene ciloleucel.
News
Rusty Patched Bumble Bee Is Listed as Endangered
The rusty patched bumble bee has become the first-ever bumble bee in the United States, and the first bee of any kind in the contiguous 48 states, to be declared endangered.
News
Vaginal Microbes May Play Role in Endometrial Cancer
First ever direct assessment of the uterine microbiome identifies possible tools for the early detection of endometrial cancer.
News
Researchers in Japan Have Discovered an Enzyme That Can Prevent Obesity in Mice
Researchers at the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology in Japan have discovered an enzyme that can prevent obesity in mice.
News
Timing is Everything in Phage Therapy
Mathematical model sheds light on the timing of key, intracellular events.
News
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
Mylan (UK) and Biocon's (IND) license application for biosimilar to branded trastuzumab for the treatment of HER2-positive breast cancers receives FDA acceptance.
Advertisement